IR@PKUHSC  > 北京大学首钢医院
学科主题临床医学
Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: an updated meta-analysis
Li, Peng1; Liu, Jun-Peng2
关键词diabetes everolimus-eluting stent major adverse cardiac event paclitaxel-eluting stent very late stent thrombosis
刊名CORONARY ARTERY DISEASE
2014-08-01
DOI10.1097/MCA.0000000000000109
25期:5页:369-377
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Peripheral Vascular Disease
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]CORONARY-ARTERY-DISEASE ; COMPREHENSIVE NETWORK METAANALYSIS ; BARE-METAL STENTS ; XIENCE V ; FOLLOW-UP ; CLINICAL-EVALUATION ; TRIAL ; OUTCOMES ; INTERVENTION ; SYSTEM
英文摘要

Objectives Everolimus-eluting stent (EES) reduces the risk of late and very late stent thrombosis (ST) in a number of randomized controlled trials (RCTs). However, the benefits have been variable.

Materials and methods We evaluated the effect of EES and paclitaxel-eluting stent (PES) on the risk of late and very late ST in patients with coronary artery disease.

Results We identified RCTs by a systematic search of MEDLINE, EMBASE, and Cochrane Database. Seven RCTs (8162 patients) were included. Overall, EES therapy lowered the risk of very late ST significantly [relative risk (RR), 0.40; 95% confidence interval (CI), 0.20-0.80; I-2 = 0.0%; P = 0.009] compared with PES. Meanwhile, EES was associated with a significantly lower incidence of major adverse cardiac events (RR, 0.76; 95% CI, 0.67-0.86; I-2 = 34.2%; P = 0.00) driven by a markedly lower rate of myocardial infarction and target-vessel revascularization in the EES group. However, there was no significant difference in the risk of late ST (RR, 0.45; 95% CI, 0.15-1.39; I-2 = 30.7%; P = 0.166) between the two groups. A subgroup analysis showed that EES might not decrease the risk of very late ST significantly in patients older than 63.5 years or in patients with diabetes, those presenting with acute coronary syndrome, or those with a longer follow-up.

Conclusion Compared with PES, EES treatment decreased risk of very late ST significantly. However, the risk of late ST was similar between the two groups. More studies are needed to confirm the subgroup findings. (C) 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.

语种英语
WOS记录号WOS:000339652100003
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65036
专题北京大学首钢医院
作者单位1.Beijing Hosp, Dept Cardiol, Beijing 100730, Peoples R China
2.Peking Univ, Shougang Hosp, Dept ICU, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Li, Peng,Liu, Jun-Peng. Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: an updated meta-analysis[J]. CORONARY ARTERY DISEASE,2014,25(5):369-377.
APA Li, Peng,&Liu, Jun-Peng.(2014).Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: an updated meta-analysis.CORONARY ARTERY DISEASE,25(5),369-377.
MLA Li, Peng,et al."Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: an updated meta-analysis".CORONARY ARTERY DISEASE 25.5(2014):369-377.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Peng]的文章
[Liu, Jun-Peng]的文章
百度学术
百度学术中相似的文章
[Li, Peng]的文章
[Liu, Jun-Peng]的文章
必应学术
必应学术中相似的文章
[Li, Peng]的文章
[Liu, Jun-Peng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。